Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longboard Pharmaceuticals Inc (NQ: LBPH ) 36.42 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Longboard Pharmaceuticals Inc < Previous 1 2 Next > Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome September 26, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome September 19, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) September 08, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) September 06, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September August 28, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress August 26, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024 August 26, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) August 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates August 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1 July 29, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) July 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) July 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) June 10, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) June 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 06, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates May 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 April 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) April 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates March 12, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) March 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) February 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February February 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares January 08, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire This biotech stock has surged over 300% this week January 05, 2024 Shares of Longboard Pharmaceuticals (NASDAQ: LBPH) have sky-rocketed higher this week, up over 300% thanks to breaking news Via MarketBeat Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock January 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock January 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) January 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) January 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers November 29, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community November 21, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.